Checkpoint Therapeutics (Checkpoint Therapeutics) Float Percentage Of Total Shares Outstanding : 90.73% (As of Jun. 11, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Checkpoint Therapeutics's float shares is 33.43 Mil. Checkpoint Therapeutics's total shares outstanding is 36.85 Mil. Checkpoint Therapeutics's float percentage of total shares outstanding is 90.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Checkpoint Therapeutics's Insider Ownership is 8.92%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Checkpoint Therapeutics's Institutional Ownership is 6.03%.

Checkpoint Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Checkpoint Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	33.43	/	36.85
	=	90.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

CZTA:Germany CZTA:Germany

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Executives

William Garrett Gray	officer: See Remarks	2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii	director, officer: CEO, President and Director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon	director	C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman	director	464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen	director	2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020